We help pharma companies source, evaluate and execute
in- and out-licensing deals across Europe.

Faster. With better data. And a network built over 15 years at the top of the European generics industry.

15+Years in European pharma BD
3Active investment projects
EU+Partner network across Europe & Asia

Three ways we work with you

We don't describe services — we deliver outcomes. Here's what you get.

🔍
In-licensing Scouting
Monthly retainer

We actively scan the European market for products that match your portfolio criteria — generics, OTC, or specialty. You get a structured opportunity report every month with commercial, regulatory and supply assessment included.

  • Shortlisted opportunities with scoring
  • Initial partner outreach handled
  • Commercial and patent pre-screening
Get started →
🚀
Nordic Launch Package
Project-based

From MA strategy to first sale — we manage the full Nordic market entry for your product. Regulatory pathway, distributor selection, pricing, channel setup and launch plan. One point of contact. Fixed scope.

  • Full Nordic regulatory strategy
  • Distributor and partner identification
  • Launch plan with KPIs and timeline
Get started →
BD Due Diligence Sprint
2–4 weeks

You've found a potential asset, partner or deal. We run a structured commercial and regulatory due diligence — fast. You get a clear go/no-go recommendation with the data to back it up.

  • Commercial market sizing
  • Regulatory risk assessment
  • Supply chain and patent review
Get started →

Our killer differentiator

Access curated pharma opportunities from across Europe

We track a continuously updated portfolio of in-licensing and partnership opportunities — products with existing EU dossiers, validated clinical data, and identified suppliers. Our BD teams use it to shortcut months of sourcing work.

ActiveDossiers tracked
EU+Geographies covered
Rx+OTCCategories
View available products →
ProductDossierMarket
Adenosine 3mg/mlReady · MRPEU excl. 6
Clonidine oralQ3 / 2026Excl. UK/ANZA
Tizanidine tabsQ4 / 2026Excl. UK/ANZA
Bumetanide tabsQ1 / 2027Excl. Nordics
+ more products available →

Dan Kyster Hartwig
Who you work with

Dan Kyster Hartwig

Founder · DH Nordic Pharma Consultancy

15+ years as Head of Business Development at two of Denmark's largest generics companies — Orifarm Generics and 2care4. Closed licensing, supply and asset deals across Europe and Asia. Member of the board at Orifarm Group.

Today I work as a fractional BD partner for pharma companies that need senior execution without a full-time hire.


Ready to talk?

A 30-minute call costs nothing. Let's find out if we're a fit.